We described the histopathological morphology of FTMT breast tissue. The frequency of carcinoma and hyperplasia did not differ significantly between FTMT women who had used androgen therapy and those who had not. These findings suggest that androgen does not alter the risk of carcinoma developing in the mammary glands of FTMT women.

Our series included more small size carcinomas than did previous series. Lymph node status does not appear to be markedly different from that of the usual invasive ductal carcinomas. Her2/neu expression was similar to that found in common breast carcinomas.

While our series is too small to make conclusions about the behavior of IMC, the difference in 6-year survival rate between the patients with IMC and those with breast carcinoma in general was statistically significant. Recognition of this distinctive and aggressive variant of infiltrating carcinoma is important because of its poor prognosis and high incidence of lymph node metastases.